Biogen’s Revolutionary Multiple Sclerosis Treatment Clears First Hurdle

Biogen's (NASDAQ: BIIB  ) 48% return over the last 12 months can largely be chalked up to investor optimism surrounding its oral multiple sclerosis drug Tecfidera (formerly referred to as BG-12). Today, the company happily announced that the EU's CHMP recommended approval for the drug's use in Europe. With an FDA decision on this same drug just around the corner, could Tecfidera soon be available to patients on both sides of the Atlantic?

In the following video, Motley Fool health-care analyst Max Macaluso discusses what this decision means for Biogen, and how this drug might compete with the current market leaders in the multiple sclerosis space.

What macro trend was Warren Buffett referring to when he said,This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating at America's Competitiveness. You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2328150, ~/Articles/ArticleHandler.aspx, 10/2/2014 2:49:11 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement